JPWO2020202038A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020202038A5 JPWO2020202038A5 JP2021558768A JP2021558768A JPWO2020202038A5 JP WO2020202038 A5 JPWO2020202038 A5 JP WO2020202038A5 JP 2021558768 A JP2021558768 A JP 2021558768A JP 2021558768 A JP2021558768 A JP 2021558768A JP WO2020202038 A5 JPWO2020202038 A5 JP WO2020202038A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- antigen
- binding fragment
- pharmaceutical composition
- oleculumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025166226A JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828177P | 2019-04-02 | 2019-04-02 | |
| US62/828,177 | 2019-04-02 | ||
| PCT/IB2020/053110 WO2020202038A1 (en) | 2019-04-02 | 2020-04-01 | Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166226A Division JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527334A JP2022527334A (ja) | 2022-06-01 |
| JPWO2020202038A5 true JPWO2020202038A5 (https=) | 2023-11-08 |
| JP2022527334A5 JP2022527334A5 (https=) | 2023-11-08 |
Family
ID=72663659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558768A Pending JP2022527334A (ja) | 2019-04-02 | 2020-04-01 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
| JP2025166226A Pending JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166226A Pending JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200317803A1 (https=) |
| EP (1) | EP3947447A4 (https=) |
| JP (2) | JP2022527334A (https=) |
| KR (1) | KR20210148253A (https=) |
| CN (2) | CN113993890A (https=) |
| AU (2) | AU2020254100B9 (https=) |
| CA (1) | CA3134671A1 (https=) |
| EA (1) | EA202192587A1 (https=) |
| IL (1) | IL286504A (https=) |
| MA (1) | MA55558A (https=) |
| SG (1) | SG11202110694RA (https=) |
| TW (1) | TW202102545A (https=) |
| WO (1) | WO2020202038A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116209468A (zh) * | 2020-09-23 | 2023-06-02 | 免疫医疗有限责任公司 | 使用抗cd73和抗pd-l1抗体和化疗的治疗方法 |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2023227115A1 (en) * | 2022-05-26 | 2023-11-30 | I-Mab Biopharma Co., Ltd. | A method of treating solid tumor |
| EP4626552A1 (en) * | 2022-12-01 | 2025-10-08 | MedImmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| DK3218406T4 (da) * | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| KR20230038311A (ko) * | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| FI3922279T3 (fi) * | 2016-08-30 | 2025-02-04 | Dana Farber Cancer Inst Inc | Lääkkeenantokoostumuksia ja niiden käyttötapoja |
| CN118307674A (zh) * | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
-
2020
- 2020-04-01 US US16/837,477 patent/US20200317803A1/en not_active Abandoned
- 2020-04-01 KR KR1020217035422A patent/KR20210148253A/ko active Pending
- 2020-04-01 JP JP2021558768A patent/JP2022527334A/ja active Pending
- 2020-04-01 WO PCT/IB2020/053110 patent/WO2020202038A1/en not_active Ceased
- 2020-04-01 CN CN202080039845.5A patent/CN113993890A/zh active Pending
- 2020-04-01 TW TW109111394A patent/TW202102545A/zh unknown
- 2020-04-01 EA EA202192587A patent/EA202192587A1/ru unknown
- 2020-04-01 CN CN202510064168.7A patent/CN119857140A/zh active Pending
- 2020-04-01 CA CA3134671A patent/CA3134671A1/en active Pending
- 2020-04-01 AU AU2020254100A patent/AU2020254100B9/en active Active
- 2020-04-01 MA MA055558A patent/MA55558A/fr unknown
- 2020-04-01 EP EP20783214.8A patent/EP3947447A4/en not_active Withdrawn
- 2020-04-01 SG SG11202110694RA patent/SG11202110694RA/en unknown
-
2021
- 2021-09-19 IL IL286504A patent/IL286504A/en unknown
-
2025
- 2025-01-06 AU AU2025200063A patent/AU2025200063A1/en active Pending
- 2025-10-02 JP JP2025166226A patent/JP2026031542A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woo et al. | Metronomic chemotherapy in metastatic colorectal cancer | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| JP2021510725A5 (https=) | ||
| TW201107327A (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2021530502A5 (https=) | ||
| CN110290802A (zh) | [6r]-mthf-在基于5-氟尿嘧啶的化学疗法中的有效叶酸替代物 | |
| JPWO2020202038A5 (https=) | ||
| Takashima et al. | Standard first-line chemotherapy for metastatic gastric cancer in Japan has met the global standard: evidence from recent phase III trials | |
| Iwase et al. | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer | |
| Harada et al. | Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Non–Small-Cell Lung Cancer | |
| Turkington et al. | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma | |
| CN113559269A (zh) | 肌苷在制备抗肿瘤药物或抗肿瘤药物组合物中的应用 | |
| Mayer et al. | Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study | |
| Liu et al. | P3. 18.75 Tislelizumab in Combination With EP/EC Chemotherapy and Sequent Anlotinib Followed by Radiotherapy as First-Line Treatment for ES-SCLC | |
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ | |
| BR112020011796A2 (pt) | uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo | |
| Choong et al. | Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer | |
| JPWO2020018789A5 (https=) | ||
| TW201836616A (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| CN107456456A (zh) | 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途 | |
| Si et al. | P1. 01-108 management of anlotinib-related adverse events: data from ALTER 0303 | |
| Socinski et al. | P-585 Long-term results of aggressive combined modality therapy employing induction and concurrent carboplatin/paclitaxel with dose-escalated thoracic conformal radiation therapy | |
| WO2025082356A1 (zh) | Cldn18_2抗体与化学治疗药物的组合及其应用 | |
| Wheater et al. | Multidisciplinary Treatment of Cancer: Chemotherapy |